21 research outputs found
Cisplatin induces loop structures and condensation of single DNA molecules
Structural properties of single λ DNA treated with anti-cancer drug cisplatin were studied with magnetic tweezers and AFM. Under the effect of low-concentration cisplatin, the DNA became more flexible, with the persistence length decreased significantly from ∼52 to 15 nm. At a high drug concentration, a DNA condensation phenomenon was observed. Based on experimental results from both single-molecule and AFM studies, we propose a model to explain this kind of DNA condensation by cisplatin: first, di-adducts induce local distortions of DNA. Next, micro-loops of ∼20 nm appear through distant crosslinks. Then, large aggregates are formed through further crosslinks. Finally, DNA is condensed into a compact globule. Experiments with Pt(dach)Cl2 indicate that oxaliplatin may modify the DNA structures in the same way as cisplatin. The observed loop structure formation of DNA may be an important feature of the effect of platinum anti-cancer drugs that are analogous to cisplatin in structure
Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy
OBJECTIVE: To determine the effect of changing from etanercept or methotrexate
monotherapy to etanercept plus methotrexate combination therapy on radiographic
progression in rheumatoid arthritis (RA) patients. METHODS: Patients enrolled in
this 1-year open-label study previously completed a 3-year blinded study in which
they received methotrexate or etanercept monotherapy or the combination of both.
All patients received the combination of etanercept 25 mg subcutaneously twice
weekly plus oral methotrexate up to 20 mg/week. The primary radiographic endpoint
was a change in modified total Sharp score (TSS), as assessed by blinded readers.
RESULTS: At baseline, patients previously receiving methotrexate monotherapy
(etanercept-added, n = 52) or etanercept monotherapy (methotrexate-added, n = 68)
had moderate disease activity levels (mean disease activity score (DAS) of 2.6
and 2.5, respectively), whereas patients previously receiving combination therapy
(n = 90) had a low disease activity level (mean DAS of 2.0). The addition of
etanercept to methotrexate monotherapy resulted in a significant reduction in
radiographic progression (p<0.05). Mean TSS changes in the previous year versus
the current year were +1.79 versus +0.25 for the etanercept-added group (p<0.05);
+0.51 versus -0.18 for the methotrexate-added group (NS) and +0.42 versus +0.24
for the combination group (NS). CONCLUSION: In these RA patients with on average
moderate disease activity despite previous methotrexate monotherapy, combination
treatment with etanercept and methotrexate inhibited radiographic progression and
improved radiographic outcomes. These data, in conjunction with the previously
published clinical data, support the use of combination therapy in RA patients
with moderate disease activity
Pilot study to assess reagent and instrument quality for reproducible diagnosis of chronic lymphocytic leukemia: an ESCCA and ERIC harmonisation project
Pilot study to assess reagent and instrument quality for reproducible diagnosis of chronic lymphocytic leukemia: an escca and eric harmonisation proje
Recommended from our members
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL